Unusual Dengue Virus 3 Epidemic in Nicaragua, 2009 by Gutierrez, Gamaliel et al.
Unusual Dengue Virus 3 Epidemic in Nicaragua, 2009
Gamaliel Gutierrez
1, Katherine Standish
1, Federico Narvaez
2, Maria Angeles Perez
2, Saira Saborio
3,
Douglas Elizondo
1, Oscar Ortega
1, Andrea Nun ˜ez
3, Guillermina Kuan
4, Angel Balmaseda
3, Eva Harris
5*
1Sustainable Sciences Institute, Managua, Nicaragua, 2Unidad de Infectologı ´a, Hospital Infantil Manuel de Jesu ´s Rivera, Ministry of Health, Managua, Nicaragua,
3Laboratorio Nacional de Virologı ´a, Centro Nacional de Diagno ´stico y Referencia, Ministry of Health, Managua, Nicaragua, 4Centro de Salud So ´crates Flores Vivas,
Ministry of Health, Managua, Nicaragua, 5Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, United
States of America
Abstract
The four dengue virus serotypes (DENV1–4) cause the most prevalent mosquito-borne viral disease affecting humans
worldwide. In 2009, Nicaragua experienced the largest dengue epidemic in over a decade, marked by unusual clinical
presentation, as observed in two prospective studies of pediatric dengue in Managua. From August 2009–January 2010, 212
dengue cases were confirmed among 396 study participants at the National Pediatric Reference Hospital. In our parallel
community-based cohort study, 170 dengue cases were recorded in 2009–10, compared to 13–65 cases in 2004–9. In both
studies, significantly more patients experienced ‘‘compensated shock’’ (poor capillary refill plus cold extremities,
tachycardia, tachypnea, and/or weak pulse) in 2009–10 than in previous years (42.5% [90/212] vs. 24.7% [82/332] in the
hospital study (p,0.001) and 17% [29/170] vs. 2.2% [4/181] in the cohort study (p,0.001). Signs of poor peripheral
perfusion presented significantly earlier (1–2 days) in 2009–10 than in previous years according to Kaplan-Meier survival
analysis. In the hospital study, 19.8% of subjects were transferred to intensive care, compared to 7.1% in previous years –
similar to the cohort study. DENV-3 predominated in 2008–9, 2009–10, and 2010–11, and full-length sequencing revealed no
major genetic changes from 2008–9 to 2010–11. In 2008–9 and 2010–11, typical dengue was observed; only in 2009–10 was
unusual presentation noted. Multivariate analysis revealed only ‘‘2009–10’’ as a significant risk factor for Dengue Fever with
Compensated Shock. Interestingly, circulation of pandemic influenza A-H1N1 2009 in Managua was shifted such that it
overlapped with the dengue epidemic. We hypothesize that prior influenza A H1N1 2009 infection may have modulated
subsequent DENV infection, and initial results of an ongoing study suggest increased risk of shock among children with
anti-H1N1-2009 antibodies. This study demonstrates that parameters other than serotype, viral genomic sequence, immune
status, and sequence of serotypes can play a role in modulating dengue disease outcome.
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Introduction
Dengue is an increasing public health problem in tropical and
sub-tropical regions, with tens of millions of cases estimated to
occur annually [1]. The four serotypes of dengue virus (DENV-
1–4), a mosquito-borne Flavivirus, cause a range of clinical
manifestations, from undifferentiated illness and classic Dengue
Fever, to more severe syndromes characterized by plasma
leakage, shock, and death, referred to as Dengue Hemorrhagic
Fever and Dengue Shock Syndrome (DHF/DSS) [2]. While
serotype and dengue immune status have been shown to affect
severity of disease [3,4,5,6], many of the epidemiologic and
clinical variations in the presentation of dengue remain poorly
understood.
Dengue transmission has increased dramatically in Nicaragua
and much of the rest of the Americas in the past three decades.
All four serotypes now circulate in Nicaragua, though unlike
Asia, where dengue is hyperendemic [3,7], one serotype usually
predominates each year [8,9,10,11,12]. The dengue season
starts some months after the first rains, and typically lasts from
August to January. In 2004–2008, several thousand cases of
laboratory-confirmed dengue were reported annually by the
National Epidemiologic Surveillance program, though actual
numbers of cases are suspected to be much higher [13].
Approximately 2–10% of laboratory-confirmed dengue cases were
the more severe dengue hemorrhagic fever (DHF) or dengue shock
syndrome (DSS), and less than 1% resulted in death (A. Nun ˜ez
and A. Balmaseda, unpublished data).
In 2009–10, Nicaragua experienced one of the largest dengue
epidemics since the virus was reintroduced into the country in
the 1980s, with approximately 3 times as many laboratory-
confirmed cases reported by national authorities and document-
ed in our studies than in the previous five years. The same
serotype, DENV-3, was responsible for the majority of cases in
the 2008–9, 2009–10, and 2010–11 seasons, but caused an
atypical clinical presentation only in 2009–10, characterized
primarily by early signs of poor peripheral perfusion and what is
designated ‘‘compensated shock’’. Here we present epidemiologic
and clinical data from two on-going prospective studies of
pediatric dengue in Managua, Nicaragua, that define the
characteristics of the epidemic and begin to investigate possible
explanations.
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Cohort Study
The Pediatric Dengue Cohort Study is a community-based
prospective study that was initiated in 2004 in the low- to middle-
income District II of Managua, Nicaragua, close to Lake
Nicaragua, in which most residents attend the local municipal
health center, the Health Center Socrates Flores Vivas (HCSFV).
Children aged two to nine years old living in the catchment area of
the HCSFV were initially enrolled in August–September 2004,
and new 2-year olds have been enrolled each year since then.
Children are withdrawn from the study when they reach 15 years
of age. Study design and methods have been previously described
[14].
Participants are encouraged to present at the first sign of illness
to the HCSFV, where study physicians screen them for signs and
symptoms of dengue and presence of warning signs for severity
using a standardized data collection form. Subjects are followed
daily during the acute phase of illness by physicians at the HCSFV
or via home visits by study nurses. Acute and convalescent (14 days
after onset of fever) blood samples are drawn for virological,
serological, and molecular biological testing for dengue, and
additional blood samples are drawn every other day during the
acute phase of illness for Complete Blood Count (CBC) and blood
chemistry tests as warranted. Participants are transferred to the
National Pediatric Reference Hospital in Managua (Hospital
Infantil Manuel de Jesu ´s Rivera, HIMJR) if warning signs or risk
factors are present (see below). Trained study physicians and
nurses also collect data using standardized forms at the HIMJR.
Additionally, each year in July–August, a healthy blood sample is
drawn from all subjects. Sera from consecutive annual samples are
tested for the presence of anti-DENV antibodies to identify silent
transmission during the year and to determine dengue immune
status.
Hospital-Based Study
Beginning in 1998, a prospective study of pediatric dengue has
been carried out in the Infectious Disease Ward of the HIMJR to
study clinical, immunological and viral risk factors for severe
dengue [9,10,15,16,17,18]. This report focuses on data from
August 2005 through January 2010. Children between six months
and 14 years of age with suspected dengue (,7 days of illness) and
who are not actively enrolled in the concurrent cohort study are
eligible to participate in the hospital study. Both in-patient and
out-patient subjects are enrolled each year during the dengue
season (August–January) and followed clinically through the acute
phase of illness.
Upon enrollment, a medical history is taken and a complete
physical exam is performed. Clinical data, including vital signs,
symptoms, fluid balance and treatment, are recorded daily on
standardized data collection forms during hospitalization or
through daily ambulatory follow-up visits by the same team of
study physicians and nurses responsible for care of hospitalized
cohort study participants. Acute blood samples are taken daily for
CBC and serological, virological, and molecular biological testing
for DENV infection, and ultrasound and/or X-rays are performed
daily. Participants requiring more intensive therapies are trans-
ferred to the intensive care unit (ICU). A convalescent-phase blood
sample (two weeks after presentation to hospital) is also collected.
Ethics Statement
The protocols for both studies were reviewed and approved by
the Institutional Review Boards (IRB) of the University of
California, Berkeley, and of the Nicaraguan Ministry of Health;
additionally, the cohort study protocol was reviewed and approved
by the IRB of the International Vaccine Institute in Seoul, South
Korea. Parents or legal guardians of all subjects in both studies
provided written informed consent, and subjects 6 years of age and
older provided assent.
Laboratory Assays
Acute-phase serum samples are tested for DENV RNA using a
nested reverse transcriptase–polymerase chain reaction (RT-PCR)
directed to the capsid gene, which also permits identification of
serotype [19]. Samples positive by RT-PCR are processed for viral
isolation by inoculation onto Ae. albopictus C6/36 cells [20]. Paired
acute- and convalescent-phase samples are tested for anti-DENV
IgM antibodies using an in-house IgM capture ELISA [21] and for
total anti-DENV antibodies by Inhibition ELISA [11,22]. The
presence of anti-influenza A H1N1 2009 antibodies in paired
acute- and convalescent-phase samples from 2009–10 DENV-
positive hospital subjects was determined using the hemagglutina-
tion inhibition assay [23]. The antigen used was prepared using
Nicaraguan strain A/Managua/2339.03 09-H1N1-SW and is
specific for the H1N9 2009 strain of Influenza A (S. Saborio and
A. Balmaseda, unpublished data).
Sequencing and Phylogenetic Analysis
DENV isolates were sequenced at the Broad institute using a
combination of Sanger sequencing and high-throughput (454/
Roche) pyrosequencing. Sequences were aligned using Muscle
[24], with parameters optimized for maximum accuracy (i.e., no
limit was specified for runtime or iteration count). Aligned
sequences were clustered using phyML [25] with the following
parameters: (a) substitution model=HKY85, (b) number of
substitution categories=four, (c) proportion of invariant sites=-
zero, and (d) estimated values for equilibrium frequency,
transition/transversion ratio and gamma shape parameter.
Author Summary
Dengue is the most prevalent mosquito-borne viral
disease affecting humans worldwide. The four dengue
virus serotypes (DENV1–4) cause Dengue Fever and more
severe life-threatening syndromes. In 2009, Nicaragua
experienced the largest dengue epidemic in over a
decade. In a hospital-based study and community-based
prospective cohort study of pediatric dengue in the
capital, Managua, we observed unusual clinical presenta-
tion of dengue. Significantly more patients experienced
‘‘compensated shock’’ (poor capillary refill plus cold
extremities, rapid heartbeat, elevated respiratory rate,
and/or weak pulse) in 2009–10 than in previous years.
These signs of poor peripheral perfusion presented
significantly earlier and more children were transferred to
intensive care in 2009–10 than in previous years. DENV-3
was the predominant serotype in Managua in 2008–9,
2009–10 and 2010–11, but full-length sequencing revealed
no major genetic changes. In 2008–9 and 2010–11, typical
dengue was observed; only in 2009–10 was unusual
presentation noted. Since pandemic influenza A H1N1-
2009 overlapped with the dengue epidemic in Nicaragua,
we hypothesize that prior influenza A H1N1-2009 infection
may have modulated subsequent DENV infection, and
preliminary results appear to support this hypothesis. This
study demonstrates that parameters other than DENV
serotype, viral genomic sequence, immune status, and
sequence of serotypes can play a role in modulating
dengue disease.
Unusual Dengue Epidemic in Nicaragua
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In these studies, a suspected dengue case was considered
positive if it met one of the following criteria: DENV was isolated;
DENV RNA was detected through RT-PCR; seroconversion of
DENV-specific IgM was detected in paired acute- and convales-
cent-phase samples; or antibody titer by Inhibition ELISA
demonstrated a 4-fold or greater increase in titer between acute
and convalescent sera [9]. Primary DENV infections were those in
which acute antibody titer was ,10 or convalescent antibody titer
was ,2,560 and secondary infections were those in which
antibody titer was $10 (acute) or $2,560 (convalescent) as
determined by Inhibition ELISA [12]. Hospital cases from 2009–
10 were considered positive for anti-influenza A H1N1 2009
antibodies if the HI titer was $20 in acute samples or if
seroconversion or a $4-fold increase in HI titer was observed in
paired acute and convalescent samples.
In 2004–9, cohort subjects presenting to the HCSFV were
referred to the HIMJR, and hospital study participants were
hospitalized, if they presented any of the following warning signs:
persistent vomiting; moderate-to-severe dehydration; signs or
symptoms of shock; abdominal pain; breathing difficulties;
moderate-to-severe hemorrhagic manifestations; neurological
manifestations; thrombocytopenia (platelet count #100,000 plate-
lets/mL); or hematocrit $20% of normal value for age and sex.
Children with known risk factors were also referred to the hospital,
including those who were overweight and/or under one year of
age. During the 2009–10 dengue epidemic, national health
authorities mandated primary care physicians to refer all suspected
dengue cases with the above signs of alarm to the hospital,
regardless of clinical laboratory results, and hospitals to admit all
referrals from health centers for observation.
All laboratory-confirmed cases without signs of severity were
classified as dengue fever (DF), including cases presenting as
undifferentiated fever. Severity was categorized according to the
1997 WHO guidelines [2]: Dengue Hemorrhagic Fever (DHF;
hemorrhagic manifestations, platelet count #100,000 platelets/
mL, and evidence of plasma leakage) and Dengue Shock Syndrome
(DSS; DHF with circulatory disturbance evidenced by hypoten-
sion for age or narrow pulse pressure accompanied by clinical
signs of shock). In addition, included here among categories of
severe dengue are ‘‘Dengue with Signs Associated with Shock’’
(DSAS; DF with hypotension or narrow pulse pressure plus one or
more of the following: capillary refill .2 seconds, cold extremities,
or weak pulse) [9] and ‘‘Dengue Fever with Compensated Shock
(DFCS; DF with capillary refill .2 sec plus cold extremities, poor
or impalpable pulse, tachycardia, and/or tachypnea (increased
breathing rate for age) on the same day). While clinical
classifications by study physicians were assigned at discharge,
here we present classifications determined by applying algorithms
for DHF, DSS, DSAS and DFCS to clinical data ex post facto.
Separate from DFCS as a disease classification, patients were
considered to have experienced ‘‘compensated shock’’ if they
presented with capillary refill .2 sec plus cold extremities, poor or
impalpable pulse, tachycardia, and/or tachypnea on the same day;
this state could or could not evolve into hypotensive shock
depending on treatment and patient response. Thus, cases
classified as DHF, DSS or DSAS may have experienced
compensated shock during the course of illness.
Delayed capillary refill, a sign of vasoconstriction and low blood
volume, was the key clinical criteria for compensated shock, along
with signs of circulatory distress, including cold extremities. In this
study, study physicians and nurses used standard techniques of
observation. Capillary refill time was determined by the clinician
by briefly pressing on the pad of the patient’s index finger and
counting the number of seconds before normal color returned.
Cold extremities is defined as lower than normal skin temperature
and was observed by the clinician by touching with the dorsal side
of the hand the patient’s extremities, most commonly the plantar
side of the foot. Cold and clammy skin, which is included in the
variable cold extremities here, was also observed by palpating the
plantar region of the inferior extremities with the dorsal side of the
hand to sense coldness, clamminess, and sweat.
Data Analysis
Demographic and clinical characteristics of dengue cases in
both studies are presented by dengue season, defined in the year-
round cohort study as July 1–June 30 of each year in years 2005–
2010 and August 1, 2004–June 30, 2005 in the first year of the
study. In the hospital-based study, the dengue season is defined as
August 1–January 31, months corresponding to the highest
incidence of symptomatic DENV infection, when study enrollment
occurs (clinical follow-up continues through the month of
February each year). Total and age-stratified incidence in the
cohort study were calculated using laboratory-confirmed dengue
cases and the number of participants active at the time of the
annual healthy blood sample collected in July of each year.
Univariate and bivariate analyses were performed comparing
cases during the 2009–10 dengue season to cases in previous
dengue seasons. For bivariate comparison of cases across seasons,
chi squared and Fisher’s exact tests were applied to categorical
variables, while the t-test and non-parametric Mann-Whitney test
Figure 1. Dengue epidemics in prospective pediatric studies in
Managua, Nicaragua, 2004–10. A, Number of confirmed dengue
cases by month, cohort study, 2004–10; B, number of confirmed
dengue cases by month, hospital study, 2005–10.
doi:10.1371/journal.pntd.0001394.g001
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analysis of symptom presentation by day was performed
controlling for early presentation, defined as presenting to hospital
or health center in the first 3 days after onset of symptoms. Log-
rank tests were performed to compare survival curves, and Cox
regression models were created to determine risk factors associated
with ‘‘compensated shock’’, poor capillary refill, and cold
extremities, controlling for dengue season, serotype, immune
response, age, sex, and early presentation. Dummy variables were
created for categorical variables with more than 2 values, utilizing
as the reference the variable that presented least risk. Risk factors
associated with DFCS as a disease classification were estimated
using generalized linear model (GLM) multivariate analysis,
controlling for the same variables as above. Confidence levels of
95% were used. In both studies, data were stored in Microsoft
Access 2003, and statistical analyses were performed using
Intercooled Stata, Version 9 (StataCorp).
Results
General Characteristics of the 2009–10 Epidemic
Between August 2009 and June 2010, 170 laboratory-
confirmed, symptomatic cases of dengue were identified among
the 3,711 active cohort participants, with 97.7% occurring
between August and February (Fig. 1A). Overall, a dengue case
incidence of 4.6% was observed, compared to 0.4–1.8% in 2004–9
(between 13 and 65 cases each dengue season, Table 1). In the
concurrent hospital-based study, 212 (54% of enrolled partici-
pants) dengue cases were confirmed among 396 study participants
during the enrollment period spanning August 2009–January 2010
Table 1. Characteristics of confirmed dengue cases, Cohort Study, 2004–10, and Hospital Study, 2005–2010.
Cohort Study Hospital Study
2004–9 2009–10 p-value
5 2005–9 2009–10 p-value
5
n( % ) n( % ) n( % ) n( % )
Symptomatic dengue cases (% annual incidence)
1 181 (0.4–1.8) 170 (4.6) 332 212
Sex 0.641 1.000
Female 86 (47.5) 85 (50.0) 166 (50.0) 106 (50.0)
Male 95 (52.5) 85 (50.0) 166 (50.0) 106 (50.0)
Age, years (mean, SE) 7.2 (2.6) 8.2 (3.0) 0.002 8.4 (4.8–11.5) 8.6 (5.2–10.8) 0.8831
Serotype
2
DENV-1 35 (21.5) 18 (10.7) 0.007 35 (11.8) 10 (5.1) 0.011
DENV-2 106 (65.0) 9 (5.4) ,0.001 150 (50.5) 11 (5.6) ,0.001
DENV-3 19 (11.7) 141 (83.9) ,0.001 112 (37.7) 175 (88.8) ,0.001
DENV-4 1 (0.6) 0 (0.0) ---- 0 (0.0) 0 (0.0) ----
DENV 1 & 4 1 (0.6) 0 (0.0) ---- 0 (0.0) 0 (0.0) ----
DENV 1 & 2 1 (0.6) 0 (0.0) ---- 0 (0.0) 0 (0.0) ----
DENV-3 & 4 0 (0.0) 0 (0.0) ---- 0 (0.0) 1 (0.5) ----
Immune Response
3 0.424 ,0.001
Primary 77 (43.3) 78 (47.6) 109 (34.1) 107 (52.2)
Secondary 101 (56.7) 86 (52.4) 211 (65.9) 98 (47.8)
Day of presentation after onset of symptoms (mean, SD) 2.2 (1.0) 2.1 (0.9) 0.9 4.6 (1.1) 3.5 (1.2) ,0.001
Care
Out-patient 157 (86.7) 91 (53.5) ,0.001 58 (17.5) 29 (13.7) 0.239
In-patient 22 (12.2) 60 (35.3) ,0.001 258 (77.7) 141 (66.5) 0.004
Intensive care
4 2 (1.1) 19 (11.2) ,0.001 16 (7.1) 42 (19.8) ,0.001
Classification
Dengue Fever (DF) 161 (88.9) 126 (74.1) ,0.001 164 (49.4) 104 (49.1) 0.938
Dengue Fever with Compensated Shock (DFCS) 4 (2.2) 15 (8.8) 0.005 23 (6.9) 50 (23.6) ,0.001
Dengue w/Signs Associated w/Shock (DSAS) 3 (1.7) 10 (5.9) 0.032 16 (4.8) 28 (13.2) ,0.001
Dengue Hemorrhagic Fever (DHF) 9 (5.0) 12 (7.1) 0.409 82 (24.7) 24 (11.3) ,0.001
Dengue Shock Syndrome (DSS) 4 (2.2) 7 (4.1) 0.303 47 (14.2) 6 (2.8) ,0.001
1Incidence has only been calculated in the cohort study, in which between 3,497 and 3753 subjects were active in each of the six study years, corresponding to
symptomatic dengue incidence of 0.48% in 2004–5, 1.82% in 2005–6, 0.37% in 2006–7, 1.82% in 2007–8, 0.59% in 2008–9 and 4.61% in 2009–10.
2In the cohort study, serotype is known for 14 cases in 2004–5, 56 cases in 2005–6, 10 cases in 2006–7, 62 cases in 2007–8, 21 cases in 2008–9 and 170 cases in 2009–10.
In the hospital study, serotype was identified in 46, 43, 69, 139 and 197 cases in years 2005–6 through 2009–10, respectively.
3In the cohort study, immune response is indeterminate for one case in each year, 2006–7, 2007–8 and 2008–9, and in 6 cases in 2009–10. In the hospital study, immune
response is known in 55, 46, 72, 147 and 203 cases in years 2005–6 through 2009–10, respectively.
4In 2005–6 and 2006–7, cases requiring intensive care were not documented in the hospital study.
5p-values were calculated using the Chi-square tests except for mean age and mean day of presentation, for which Mann-Whitney t-tests were applied.
doi:10.1371/journal.pntd.0001394.t001
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calculation of incidence, surveillance records indicate that 5–10
times more suspected dengue cases presented to the HIMJR in
2009–10 than in previous study years (A. Balmaseda and M.A.
Perez, unpublished data). The greatest numbers of cases were
observed in September and October in both studies (Fig. 1A and
B). As in previous years, dengue was distributed evenly by gender
(50.0% were female in both studies), and cases were encountered
in subjects of all ages. The mean age of dengue cases in the cohort
was greater in 2009–10 due to aging of the cohort, which by then
extended to 13–14 years of age; no such age variation is seen in the
hospital study, where subject ages were constant through all 5
years of the study.
DENV-3 caused 88.8% (hospital study) and 83.9% (cohort) of
cases in 2009–2010. DENV-1 and -2 were also responsible for
cases in both studies in 2009–10, and one subject in the hospital
study was positive for both DENV-3 and DENV-4 (Table 1).
Roughly half of dengue cases in both studies experienced a
primary immune response (47.6% in the cohort study and 52.2%
in the hospital study). More secondary cases were observed in both
studies prior to 2008 due to the dominant circulation of DENV-2
in 2005–8, although only in the hospital study was this difference
significant (p,0.001). A larger proportion of DENV infections in
2009–10 presented symptomatically (1 symptomatic case for every
1.2 inapparent DENV infections, as measured via the annual
healthy blood sample), as compared to 2008–9, when DENV-3
also predominated (1:9.5 symptomatic to inapparent DENV
infection ratio; p,0.001).
Clinical Presentation
In both studies, the clinical presentation of dengue was
markedly different in 2009–10 than in previous years (Table 2).
Unique to the 2009–10 season was the significantly more frequent
presentation of poor peripheral perfusion, specifically poor
capillary refill (.2 seconds) and cold extremities. Significantly
more patients experienced ‘‘compensated shock’’ (poor capillary
refill plus cold extremities, tachycardia, tachypnea, and/or weak
pulse) in 2009–10 than in 2005–8 (42.5% [90/212] vs. 24.7% [82/
332] in the hospital study (p,0.001) and 17.0% [29/170] vs. 2.2%
[4/181] in the cohort study (p,0.001)) (Table 2). In Kaplan-Meier
survival analysis, poor capillary refill and cold extremities
presented significantly earlier (1–2 days) in both studies when
controlling for day of presentation (log rank p,0.001 in both
studies, Figs. 2A and B, 3A and B). Kaplan-Meier survival analysis
of ‘‘compensated shock’’ as an entity comprising these signs
naturally yielded similar results (Fig. 2C). When controlling for
serotype, immune response and early presentation in a Cox
regression model, hospital study dengue cases in 2009–10 had 2.80
times more risk of presenting poor capillary refill (95% Confidence
Intervals (CI) 1.85–4.23; p,0.001), 2.13 times more risk of
presenting cold extremities (95%CI 1.52–3.00; p,0.001), and 2.81
times more risk of presenting ‘‘compensated shock’’ (95%CI 1.85–
4.27; p,0.001); performing the same analysis among cohort cases
produced similar results (Table 3).
In addition, thrombocytopenia was seen less frequently in 2009–
10 than in previous years in the hospital study (26.5% vs. 52.4% in
2005–9, p,0.001, Table 2), although there was a trend toward
more thrombocytopenia in the cohort study in 2009–10. Clinical
manifestations of hemorrhage were more frequently observed in
both studies in 2009–10, though this difference was only significant
in the cohort study (70.0% vs. 53.0%, p,0.01, and 84.1% vs.
78.3%, p.0.05 in the cohort and hospital studies, respectively).
Severity and Classification
In both studies, more dengue-positive children required
intensive care in 2009–10 than in previous years. In the cohort
study, 11.2% (19/170) of all cases were admitted to the ICU, while
only 1.1% (2/181) cases were transferred to intensive care in
2004–9 (p,0.001). In the hospital study, 19.8% (42/212) of
patients with confirmed dengue were transferred to intensive care
in 2009–10 compared to 7.1% (16/225) in 2007–9 (p,0.001; ICU
data is available in the hospital study beginning in 2007). This
increase in ICU transfer was due to markedly greater presentation
of ‘‘compensated shock’’ in 2009–10 than in previous years.
Children with signs of poor peripheral perfusion (‘‘compensated
shock’’) were administered crystalloid fluid IV and if unresponsive,
then colloids were given. When signs of poor peripheral perfusion
persisted, children were transferred to the ICU. In the hospital
Table 2. Clinical signs and symptoms of confirmed dengue cases in 2009–10 compared to previous years, 2004–10.
Cohort Study Hospital Study
2004–9 2009–10 p-value 2005–9 2009–10 p-value
n=181 (%) n=170 (%) n=332 (%) n=212 (%)
Hemorrhagic manifestation
1 96 (53.0) 119 (70.0) 0.001 260 (78.3) 180 (84.1) 0.057
Mucosal bleeding 28 (15.5) 49 (28.8) 0.003 61 (18.3) 37 (17.4) 0.785
Positive tourniquet test 86 (47.5) 97 (57.1) 0.07 156 (47.0) 125 (59.0) 0.006
Petechiae 51 (28.2) 79 (46.5) ,0.001 250 (75.3) 167 (78.8) 0.350
Rash 65 (35.9) 85 (50.0) 0.008 302 (91.0) 196 (92.4) 0.543
Platelets #100,000/mm
3 21 (11.7) 31 (19.0) 0.06 174 (52.4) 56 (26.5) ,0.001
Leukopenia (WBC #5,000/mm
3) 117 (65.0) 142 (87.1) ,0.001 253 (76.2) 192 (90.6) ,0.001
Cold extremities 14 (7.7) 59 (34.7) ,0.001 123 (37.1) 118 (55.6) ,0.001
Capillary refill .2 seconds 12 (6.6) 50 (29.4) ,0.001 87 (26.2) 94 (44.34) ,0.001
Compensated shock 4 (2.2) 29 (17) ,0.001 82 (24.7) 90 (42.5) ,0.001
1Hemorrhagic manifestations do not include laboratory values and include any of the following clinical signs and symptoms: petechiae, rash, positive tourniquet test,
bruising, hematoma, hemoptysis, epistaxis, gingivorrhagia, melena, hematemesis, hematuria, subconjunctival hemorrhage, vaginal hemorrhage, hypermenorrhea and
excessive bleeding at puncture site.
doi:10.1371/journal.pntd.0001394.t002
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www.plosntds.org 5 November 2011 | Volume 5 | Issue 11 | e1394Figure 2. Presentation of signs of poor peripheral perfusion in hospital study dengue cases, 2005–9 vs. 2009–10. A, cold extremities, B,
poor capillary refill (.2 sec), and C, compensated shock. Left panel, frequency of presentation by day; right panel, Kaplan-Meier survival function
adjusted for early presentation (days 1–3 after onset of fever).
doi:10.1371/journal.pntd.0001394.g002
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in 2009–10 received IV fluid therapy, and 40.7% (35/86) of those
given liquids were transferred to the ICU. In 2005–9, 83% (68/82)
of patients with ‘‘compensated shock’’ received IV fluids, of which
23% (15/68) were transferred to the ICU (during 2007–9). The
early administration of IV crystalloid and colloid fluids may well
have contributed to preventing progression to hypotensive shock.
For instance, in the hospital study, only 30% (27/90) of children
experiencing ‘‘compensated shock’’ progressed to hypotensive
shock; this could explain the reduced numbers of DHF/DSS
Figure 3. Presentation of signs of poor peripheral perfusion in the dengue cohort study, 2004–9 vs. 2009–10. A, cold extremities and B,
poor capillary refill (.2 sec). Left panel, frequency of presentation by day; right panel, Kaplan-Meier survival function adjusted for early presentation
(days 1–3 after onset of fever).
doi:10.1371/journal.pntd.0001394.g003
Table 3. Year 2009–10 as most significant risk factor in Cox regression models of compensated shock, 2004–10.
Cohort Study Hospital Study
Hazard Ratio for Year
2009–10
1 95% CI p-value
Hazard Ratio for Year
2009–10
1 95% CI p-value
Cold extremities 3.16 1.40–7.15 0.006 2.13 1.52–3.00 ,0.001
Capillary refill .2 seconds 2.93 1.21–7.06 0.017 2.80 1.85–4.23 ,0.001
Compensated shock — — 2.81 1.85–4.27 ,0.001
1Cox regression models were created to determine risk factors associated with ‘‘compensated shock’’, poor capillary refill, and cold extremities, controlling for dengue
season, serotype, immune response, age, sex, and early presentation. Year 2009–10 emerged as the most significant risk factor in all models, with values as indicated.
doi:10.1371/journal.pntd.0001394.t003
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‘‘compensated shock’’ progressed to hypotensive shock.
When children who experienced ‘‘compensated shock’’ did not
progress to hypotensive shock, they were classified as ‘‘Dengue
Fever with Compensated Shock’’ (DFCS). Significantly more cases
of DFCS were observed in 2009–10 as compared to 2004–9 in the
cohort study (15/170 [8.8%] vs. 4/181 [2.2%]) and in the hospital
study (50/212 [23.6%] vs. 23/332 [6.9%]) (Table 1 and Fig. 4).
Conversely, in the hospital study, significantly less DHF and DSS
were seen in 2009–10 (11.3% and 2.8%, respectively) compared to
2005–9 (24.7% and 14.2%, respectively, p,0.001, Table 1 and
Fig. 4B). However, more DSAS cases were seen in 2009–10 (28/
212; 13.2%) than in 2005–9 (16/332; 4.8%). Interestingly, in
2009–10, DFCS, DSAS, and DSS cases were comprised of
equivalent numbers of primary and secondary DENV infections.
Figure 4. Classification of severity among confirmed dengue
cases by year. Dengue cases were classified according to WHO
classification (Dengue Hemorrhagic Fever and Dengue Shock Syn-
drome), Dengue Fever with Compensated Shock (DFCS), and Dengue
with Signs Associated with Shock (DSAS), in A, cohort study, 2004–10,
and B, hospital study, 2005–10.
doi:10.1371/journal.pntd.0001394.g004
Table 4. Multivariate analysis of risk factors for DFCS
compared to other dengue cases, Hospital Study, 2005–10.
Relative Risk 95% CI p-value
Year 2009–10
1 3.42 1.67–7.01 0.001
Secondary immune
response
1.00 0.58–1.72 0.997
DENV-1 2.06 0.79–5.40 0.141
DENV-2 1.00 Reference value —
DENV-3 1.24 0.53–2.90 0.613
Age ,5 years 1.12 0.60–2.10 0.716
Female 0.78 0.49–1.25 0.314
Early presentation 1.02 0.61–1.73 0.912
1The reference group is years 2005–9.
doi:10.1371/journal.pntd.0001394.t004
Figure 5. Phylogenetic analysis of Nicaraguan DENV-3 se-
quences from 2008–2010. Seventeen, 82, and 28 sequences from
2008 (pink), 2009 (blue) and 2010 (teal), respectively, were aligned using
Muscle and clustered using phyML. Six isolates from Venezuela (‘‘Ven’’),
Martinique (‘‘Martinique’’), Thailand (‘‘Thai’’) and Puerto Rico (‘‘PR’’) from
the Asian-American genotype are also shown to root the tree and
demonstrate similarities among the Nicaraguan isolates.
doi:10.1371/journal.pntd.0001394.g005
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factors associated with classification as DFCS as compared to all
other dengue cases, controlling for immune status, year 2009–10
versus 2005–9, serotype, sex, and age (,5 years old), only year of
study 2009–10 emerged as significant (RR 3.42, 95%CI 1.67–
7.01; p,0.001; Table 4). Likewise, in multivariate analysis
controlling for the same variables as above, only study year
2009–10 was a significant risk factor for DFCS as compared to
uncomplicated dengue fever (RR 3.02, 95%CI 1.64–5.59;
p,0.001) or for shock (both compensated and hypotensive) as
compared to non-shock dengue cases (RR 2.42, 95%CI 1.62–3.11;
p,0.001).
DENV-3 Subanalysis in 2005–9, 2009–10 and 2010–11
Beginning in 2008–9 and continuing through 2010–11, DENV-
3 caused the majority of dengue cases in both the cohort and
hospital studies, differentiating these years from the previous study
years in which DENV-2 predominated. In 2008–9, 2009–10 and
2010–11, DENV-3 was responsible for between 74 and 97% of
cases in the hospital study, and between 80 and 90% of cases in the
cohort study. We sequenced the full-length genome of 17 DENV-3
strains from the 2008–9 dengue season, 82 strains from the 2009–
10 dengue season, and 28 samples from the 2010–11 dengue
season; phylogenetic analysis revealed no changes in genotype or
clade (Fig. 5). We then performed a sub-analysis among DENV-3
cases in the hospital study to control for the effect of serotype on
clinical presentation. Compared to cases in 2005–9 and 2010–11,
more cases in 2009–10 were referred to the ICU (3.6% and 4.8%
vs. 18.8%, p,0.001) and were classified as DFCS (7.1% and
10.6% vs. 21.2%, p,0.01) or DSAS (1.8% and 2.9% vs. 13.7%,
p,0.001; Table 5). Likewise, more DENV-3 cases in 2009–10
presented compensated shock and its associated signs, delayed
capillary refill and cold extremities, than in 2005–9 or 2010–11
(p,0.001). Kaplan-Meier survivor curves indicate that these same
Table 5. Demographic and clinical characteristics of DENV-3 cases, Hospital Study, 2005–11.
2005–9 2009–10 2010–11 p-value
3
Symptomatic dengue cases, serotype 3 112 175 104
Sex 0.861
Female 58 (51.8) 87 (49.7) 50 (48.1)
Male 54 (48.2) 88 (50.3) 88 (50.3)
Age, years (median, IQR) 7.0 (3.4–9.3) 8.6 (5.2–10.7) 8.5 (5.8–11.6) 0.003
Immune Response
1 0.805
Primary 61 (56.0) 88 (52.4) 55 (55.6)
Secondary 48 (44.0) 80 (47.6) 44 (44.4)
Day of presentation after onset of symptoms (median, IQR) 5 (4–5) 3 (2–4) 4 (3–4) ,0.001
Care
Out-patient 27 (24.1) 22 (12.6) 8 (7.7) 0.002
In-patient 81 (72.3) 120 (68.6) 91 (87.5) 0.002
Intensive care 4 (3.6) 33 (18.8) 5 (4.8) ,0.001
Classification
Dengue Fever (DF) 69 (61.6) 89 (50.9) 63 (60.6) 0.125
Dengue Fever with Compensated Shock (DFCS) 8 (7.1) 37 (21.1) 11 (10.6) 0.002
Dengue w/ Signs Associated w/Shock (DSAS) 2 (1.8) 24 (13.7) 3 (2.9) ,0.001
Dengue Hemorrhagic Fever (DHF) 27 (24.1) 20 (11.4) 25 (24.0) 0.006
Dengue Shock Syndrome (DSS) 6 (5.4) 5 (2.9) 2 (1.9) 0.386
Clinical Signs and Symptoms
Hemorrhagic manifestations
2 90 (80.4) 148 (84.6) 83 (79.8) 0.514
Mucosal bleeding 18 (16.1) 32 (18.3) 13 (12.5) 0.446
Positive tourniquet test 49 (43.7) 102 (58.3) 42 (40.4) 0.006
Petechiae 88 (78.6) 136 (77.7) 79 (76.0) 0.896
Rash 107 (95.4) 162 (92.6) 101 (97.1) 0.276
Platelets #100,000/mm
3 51 (45.5) 46 (26.3) 38 (36.5) 0.003
Leukopenia (WBC #5,000/mm
3) 86 (76.8) 162 (92.6) 94 (90.4) ,0.001
Cold extremities 32 (28.6) 92 (52.6) 39 (37.5) ,0.001
Capillary refill .2 seconds 19 (17.0) 74 (42.3) 24 (23.1) ,0.001
Compensated shock 18 (16.1) 71 (40.6) 24 (23.1) ,0.001
1In the hospital study, immune response is known in 109, 168, and 99 DENV-3 cases in years 2008–9, 2009–10, and 2010–11, respectively.
2Hemorrhagic manifestations do not include laboratory values and are defined as presence of any of the following clinical signs and symptoms: petechiae, rash, positive
tourniquet test, bruising, hematoma, hemoptysis, epistaxis, gingivorrhagia, melena, hematemesis, hematuria, subconjunctival hemorrhage, vaginal hemorrhage,
hypermenorrhea and excessive bleeding at puncture site.
3p-values were calculated using the Chi-square tests, except for mean age and mean day of presentation, for which Mann-Whitney t-tests were applied.
doi:10.1371/journal.pntd.0001394.t005
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2010–11 (Fig. 6A–C). In Cox regression models controlling for
early presentation and immune responses, cases in 2009–10 had
increased risk of compensated shock, delayed capillary refill and
cold extremities (Table 6). Finally, in multivariate analysis
adjusting for age, sex and immune status, year 2009–10 cases
had a 2.62 greater risk of developing DFCS compared with cases
in 2005–9 or 2010–11 (95% CI 1.25–5.49, p=0.011) (Table 7). In
the cohort, similar trends were seen among cases of DENV-3 in
2009–10 vs. 2010–11 (data not shown), though the small number
of cases of DENV-3 in the cohort in 2004–9 precluded a complete
analysis as in the hospital study.
2009 Influenza A H1N1 Pandemic
The atypical, early onset of compensated shock and poor
peripheral perfusion we observed is unique to the 2009–10 dengue
season, when neither DENV serotype nor clade changed. Our
leading hypothesis for what may have caused this unusual clinical
presentation is the concurrent circulation of pandemic Influenza A
during the 2009 dengue season, the only notable epidemiological
distinction that occurred in 2009. Usually, influenza peaks in
June–July [26], 2–3 months before the beginning of the annual
dengue season. However, in 2009, although Influenza A H1N1
virus began circulating in Managua in June, the influenza
pandemic was more prolonged that year [26]; incidence reached
a maximum in August and overlapped for 8–10 weeks with the
2009–10 dengue epidemic (Fig. 7A and B). One hypothesis is that
recent infection with Influenza A H1N1 2009 might have
modulated the immune response to a subsequent DENV infection.
Therefore we tested for the presence of anti-H1N1 2009
antibodies in 2009–10 hospital dengue cases. In serum samples
from 187 DENV-positive subjects in the hospital study in 2009–
10, 65.7% (123) contained antibodies specific to the Influenza A
H1N1 2009 strain, indicating recent infection with the virus.
Subjects with H1N1 antibodies had significantly greater odds of
developing compensated or hypotensive shock (DFCS, DSAS or
DSS) compared with subjects without H1N1 antibodies (43% vs.
28%, respectively; OR 1.93, 95% CI 1.01–3.31; p=0.045).
Discussion
In this paper, we have described an unusually large dengue
epidemic with a unique clinical presentation characterized by early
presentation of poor peripheral perfusion. In our pediatric cohort
study, we observed incidence rates more than twice as high as in
previous study years (4.6% vs. ,2%), a finding that reflected
observations in our parallel hospital-based study. Both the
epidemiologic and clinical trends reported in this study were also
observed by national authorities and reflected in the national
surveillance statistics for the 2009–10 dengue season in Managua.
This epidemic was associated with atypical presentation of dengue,
with signs of poor peripheral perfusion presenting 1–2 days earlier
than usual in the course of illness and less progression to DHF/
DSS in both studies. The usual evolution of dengue toward severe
disease involves rising hematocrit and falling platelet count
followed by onset of compensated shock leading to hypotensive
shock (hypotension for age or narrow pulse pressure) accompanied
by clinical signs of shock (e.g., poor capillary refill, cold
extremities). This latter is termed the critical phase and generally
occurs on days 4–5 (range 3–7) after onset of symptoms [2,27].
Compensated shock had not previously been seen on a large
scale in Nicaragua, nor has it been reported elsewhere as a
defining clinical feature of dengue without progression to
hypotensive shock. In 2009–10, study physicians treated 96% of
subjects presenting ‘‘compensated shock’’ with IV therapy
compared to 83% in previous study years. Those cases that did
not respond to crystalloid fluid therapy were administered colloids,
Figure 6. Presentation of signs of poor peripheral perfusion in
DENV-3 cases from the hospital study, 2009–10 vs. 2005–9/
2010–11. Kaplan-Meier survivor function was adjusted for early
presentation (days 1–3 after onset of fever) for A, cold extremities, B,
capillary refill .2 seconds, and C, compensated shock.
doi:10.1371/journal.pntd.0001394.g006
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the ICU, and if necessary, administered amine vasopressor agents.
Only 31% of those administered crystalloids were not responsive,
suggesting that such therapy limited progression to more severe
disease. The recently revised WHO guidelines for dengue
management suggest treatment of compensated shock with
crystalloids [27]. The early presentation of compensated shock
in the 2009–10 epidemic coupled with early IV fluid administra-
tion may well have enhanced the effect of IV fluid treatment on
the course of disease.
DENV serotype and immune response have been linked to
variations in clinical presentation of dengue. However, in this
study, in multivariate analysis controlling for serotype, immune
response, sex, and age less than 5 years, presenting in 2009–10 was
the most significant risk factor for DFCS compared with
uncomplicated dengue or all other dengue outcomes, and similar
results were obtained with DFCS, DSAS, and DSS compared to
dengue without shock. Presenting in 2009–10 was also the most
significant risk factor for early presentation of signs of poor
peripheral perfusion and compensated shock in Cox regression
models. DENV-3 was responsible for the majority of cases in the
2008–9 and 2009–10 seasons, with no change in frequency or viral
sequence. Another large dengue epidemic during the 2010–11
season was dominated by the same clade of DENV-3, yet clinical
presentation was once again typical and involved neither high
frequencies nor early presentation of ‘‘compensated shock’’ as in
2009–10. In addition, the sequence of DENV infections and
immune status appear not to be factors in the unique clinical
presentation of DENV-3 in 2009–10. In the hospital, where more
severe secondary cases are typically seen, 2009–10 had signifi-
cantly more primary infections than previous study years
(p,0.001) and similar frequencies of primary cases as in 2008–9
– consistent with the higher proportion of primary cases often
observed with DENV-3 [3,4,9]. This suggests that DENV immune
response did not impact severity, as the clinically severe cases of
2009–10 were just as likely to be primary as secondary DENV
infections. Lastly, multivariate analysis ruled out immune status
(i.e., secondary infection and thus sequence of DENV serotypes) as
responsible for the unusual clinical characteristics of dengue in
2009–10.
Thus, our data indicate that the distinct disease phenotype
observed in 2009–10 was not due to DENV serotype, viral
sequence, immune status, or serotype sequence of sequential
DENV infections and lends support to the hypothesis that
something about the year 2009–10 was different. In addition,
the ratio of symptomatic to inapparent DENV infections increased
in 2009–10 (1:1.2) relative to 2008–9 (1:9.5), implying that the
overall incidence of symptomatic DENV infection was substan-
tially higher in 2009–10. While early IV fluid intervention and
increased hospitalization may have affected disease progression,
decreasing plasma leakage and other typical symptoms of severe
disease in 2009–10, case management could not have affected the
early presentation of the symptoms of poor peripheral perfusion in
the first place, since the children arrived at the hospital with these
signs and symptoms prior to any interventions. Currently, our
favored hypothesis is that there may be an interaction between a
recent Influenza A H1N1 2009 infection and the subsequent
DENV infection, as high rates of Influenza A H1N1 2009 in the
cohort and in Managua as well as a number of identified DENV/
H1N1 2009 co-infections [28] suggest that concurrent or previous
H1N1-2009 infection may have influenced the atypical clinical
presentation of dengue cases in 2009–10. The influenza pandemic
occurred later than usual (August–September rather than June–
July) in 2009–10 and thus preceded/overlapped the annual
dengue epidemic in an unusual way that is not normally seen in
Nicaragua [26], evidenced in both the cohort and the national
surveillance system. We posit that a prior influenza infection may
be modulating the subsequent immune response to DENV
infection, perhaps by reducing interferon levels [29], which could
lead to greater DENV infection, as it is known that type I
interferons are powerful antagonists of DENV infection [30,31].
Influenza infections are known to predispose towards and enhance
the severity of secondary bacterial infections [32,33,34,35,36];
perhaps in close temporal proximity, a similar effect could occur
on a subsequent DENV infection. To investigate this hypothesis, a
case control study is underway in which acute samples from 2009
dengue cases in the cohort and hospital studies with or without
compensated/hyptotensive shock are being tested for the presence
of antibodies specific to the Influenza A H1N1 2009 strain. Initial
analyses presented here support this hypothesis. Cytokine profiles
and viremia in these samples are also being investigated. In
addition, we are establishing a mouse model of influenza virus
Table 6. Year 2009–10 as most significant risk factor in Cox regression models of compensated shock, DENV-3 cases, Hospital
Study, 2005–11.
Hazard Ratio for Year 2009–10
1 95% CI p-value
Cold extremities 2.15 1.39–3.14 ,0.001
Capillary refill .2 seconds 2.85 1.64–4.93 ,0.001
Compensated shock 2.77 1.60–4.80 ,0.001
1Cox regression models were created to determine risk factors associated with ‘‘compensated shock’’, poor capillary refill, and cold extremities in DENV-3 cases from the
Hospital study, controlling for dengue season (2009–10 and 2010–11, with 2005–9 as reference), immune response (primary versus secondary DENV infection), age (,5
versus $5 years old), sex, and early presentation (#3 days versus .3 days since onset of symptoms). Year 2009–10 emerged as the most significant risk factor in all
models, with values as indicated.
doi:10.1371/journal.pntd.0001394.t006
Table 7. Relative risk of DFCS and DFCS/DSS/DSAS in 2009–
10 in DENV-3 cases, Hospital Study.
Relative Risk
1 95% CI p-value
DFCS vs. All other dengue 2.62 1.25–5.49 0.011
DFCS vs. DF 2.37 1.17–4.81 0.017
DFCS/DSS/DSAS vs. DF/DHF 2.54 1.48–4.40 0.001
1Relative risk for the events are adjusted for dengue season (2009–10 and 2010–
11, with 2008–9 as reference), immune response (primary versus secondary
DENV infection), age (,5 versus $5 years old), sex, and early presentation (#3
days versus .3 days since onset of symptoms). Year 2009–10 emerged as the
only significant risk factor in all models, with values as indicated.
doi:10.1371/journal.pntd.0001394.t007
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mechanistic underpinnings of this proposed immunomodulation.
In summary, the 2009–10 dengue epidemic in Managua was
large and involved an atypical presentation of the disease, with
early onset of signs of poor peripheral perfusion (‘‘compensated
shock’’), as observed in both long-term community-based and
hospital studies. Multivariate analysis controlling for usual risk
factors associated with severe dengue revealed only study year
2009–10 as a significant risk factor for DFCS. Another unusual
feature of 2009 in Managua was the circulation of pandemic
influenza A H1N1, which for the first time overlapped with the
dengue season. We postulate that the unusual presentation of
dengue in 2009 may have been due in part to immunomodulation
by a prior influenza H1N1-2009 infection and are currently testing
this hypothesis. Overall, this study demonstrates that parameters
other than DENV serotype, viral genomic sequence, immune
status, and sequence of serotypes can play a role in modulating
dengue disease outcome.
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